人表皮调节素与肿瘤关系的研究进展  

Research progress on the relationship between human epiregulin and tumor

作　　者：王文萱 梁爱玲 刘勇军 WANG Wenxuan;LIANG Ailing;LIU Yongjun(Institute of Medical Technology,Guangdong Medical University,Dongguan 523808,China;Institute of Basic Medicine,Guangdong Medical University,Dongguan 523808,China)

机构地区：[1]广东医科大学医学技术学院,广东东莞523808 [2]广东医科大学基础医学院,广东东莞523808

出　　处：《广东医科大学学报》2025年第2期211-216,共6页Journal of Guangdong Medical University

基　　金：国家自然科学基金(81071853)。

摘　　要：表皮调节素(EREG)作为表皮生长因子(EGF)蛋白超家族成员之一,已被证实在多种肿瘤中的表达增加,在其发生、增殖、迁移与侵袭、耐药中发挥重要作用。EREG作为EGF家族的配体,可与相应的受体结合激活下游信号通路(如RAS/RAF/MEK、JAK/STAT3和PI3K/AKT通路),调节肿瘤的生物学行为。本文综合分析了EREG在常见肿瘤中的作用、机制及其在肿瘤微环境中的作用,以期为研究其在肿瘤的发生和治疗耐药中的作用,寻找新型分子靶点提供参考。Epiregulin(EREG),a member of the epidermal growth factor(EGF)protein superfamily,has been confirmed to have increased expression in various types of cancer and plays a significant role in the occurrence,proliferation,migration,invasion,and drug resistance of tumors.Research indicates that EREG,as a ligand of the EGF family,can bind to corresponding receptors to activate downstream signaling pathways,such as the RAS/RAF/MEK,JAK/STAT3,and PI3K/AKT pathways,thereby regulating the biological behavior of tumors.Additionally,the role of EREG in the tumor microenvironment has been elucidated.This provides new directions for studying its role in the occurrence and therapeutic resistance of cancer.This article comprehensively analyzes the role and mechanism of EREG in common cancers,providing a reference and theoretical basis for the subsequent search for novel molecular targets.

关 键 词：表皮调节素 肿瘤 肿瘤耐药 表皮生长因子 

分 类 号：R730.2[医药卫生—肿瘤]